Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD

Ophthalmology. 2013 Sep;120(9):1945-6.e1. doi: 10.1016/j.ophtha.2013.06.030.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Drug Resistance
  • Female
  • Humans
  • Intravitreal Injections
  • Male
  • Ranibizumab
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Visual Acuity / physiology
  • Wet Macular Degeneration / diagnosis
  • Wet Macular Degeneration / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab

Associated data

  • ClinicalTrials.gov/NCT00406471